[go: up one dir, main page]

NO20081212L - Xantinderivater som selektive HM74A agonister - Google Patents

Xantinderivater som selektive HM74A agonister

Info

Publication number
NO20081212L
NO20081212L NO20081212A NO20081212A NO20081212L NO 20081212 L NO20081212 L NO 20081212L NO 20081212 A NO20081212 A NO 20081212A NO 20081212 A NO20081212 A NO 20081212A NO 20081212 L NO20081212 L NO 20081212L
Authority
NO
Norway
Prior art keywords
xanthine derivatives
hm74a agonists
compounds
selective
derivatives
Prior art date
Application number
NO20081212A
Other languages
English (en)
Inventor
Andrew Mcmurtrie Mason
Ivan Leo Pinto
Jag Paul Heer
John Liddle
Shahzad Sharooq Rahman
Richard Jonathan Daniel Hatley
Ian Edward David Smith
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0516464A external-priority patent/GB0516464D0/en
Priority claimed from GB0607736A external-priority patent/GB0607736D0/en
Priority claimed from GB0614569A external-priority patent/GB0614569D0/en
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20081212L publication Critical patent/NO20081212L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Foreliggende oppfinnelse angår forbindelser med formel (I), som er xantin derivater, Fremgangsmåter for fremstilling av nevnte derivater, farmasøytiske formuleringer som innholder de aktive forbindelsene og anvendelsen av forbindelsene ved behandling, for eksempel ved behandling av sykdommer hvor underaktivering av HM74A reseptoren bidrar til sykdommen eller hvor aktivering av reseptoren vil være fordelaktig.
NO20081212A 2005-08-10 2008-03-07 Xantinderivater som selektive HM74A agonister NO20081212L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0516464A GB0516464D0 (en) 2005-08-10 2005-08-10 Novel compounds
GB0607736A GB0607736D0 (en) 2006-04-19 2006-04-19 Novel compounds
GB0614569A GB0614569D0 (en) 2006-07-21 2006-07-21 Novel compounds
PCT/EP2006/007869 WO2007017262A1 (en) 2005-08-10 2006-08-08 Xanthine derivatives as selective hm74a agonists

Publications (1)

Publication Number Publication Date
NO20081212L true NO20081212L (no) 2008-05-06

Family

ID=37189397

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20081212A NO20081212L (no) 2005-08-10 2008-03-07 Xantinderivater som selektive HM74A agonister
NO20081211A NO20081211L (no) 2005-08-10 2008-03-07 Xantinderivater som selektive HM74A agonister

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20081211A NO20081211L (no) 2005-08-10 2008-03-07 Xantinderivater som selektive HM74A agonister

Country Status (28)

Country Link
US (3) US8143264B2 (no)
EP (3) EP2272848B1 (no)
JP (2) JP2009504592A (no)
KR (2) KR20080038396A (no)
AR (1) AR055369A1 (no)
AT (1) ATE487719T1 (no)
AU (2) AU2006278215A1 (no)
BR (2) BRPI0614270A2 (no)
CA (2) CA2626723A1 (no)
CR (2) CR9749A (no)
CY (1) CY1111757T1 (no)
DE (1) DE602006018151D1 (no)
DK (1) DK1912991T3 (no)
EA (2) EA014556B1 (no)
ES (1) ES2401128T3 (no)
HR (1) HRP20100725T1 (no)
IL (2) IL189081A0 (no)
MA (2) MA29692B1 (no)
MX (2) MX2008001929A (no)
MY (1) MY142067A (no)
NO (2) NO20081212L (no)
NZ (1) NZ565494A (no)
PE (1) PE20070405A1 (no)
PL (1) PL1912991T3 (no)
PT (1) PT1912991E (no)
SI (1) SI1912991T1 (no)
TW (1) TW200800217A (no)
WO (2) WO2007017262A1 (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7495005B2 (en) * 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
CN101103030B (zh) * 2004-02-14 2010-10-13 史密丝克莱恩比彻姆公司 具有hm74a受体活性的药物
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
JP2009504592A (ja) * 2005-08-10 2009-02-05 スミスクライン・ビーチャム・コーポレイション 選択的ｈｍ７４ａアゴニストとしてのキサンチン誘導体
CN101466714B (zh) 2006-06-23 2013-02-06 英赛特股份有限公司 作为hm74a激动剂的嘌呤酮衍生物
AU2007260852B2 (en) 2006-06-23 2013-01-10 Incyte Corporation Purinone derivatives as HM74a agonists
EP2061767B1 (de) 2006-08-08 2014-12-17 Sanofi Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
US8470841B2 (en) 2008-07-09 2013-06-25 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
AU2009324811B2 (en) 2008-12-08 2013-01-24 Glaxosmithkline Llc Novel compounds
CN102482312A (zh) 2009-08-26 2012-05-30 赛诺菲 新颖的杂芳族氟代糖苷结晶水合物、含有这些化合物的药物和它们的用途
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
KR101799429B1 (ko) 2010-05-03 2017-11-21 에스케이바이오팜 주식회사 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
AU2011292285A1 (en) * 2010-08-16 2013-01-31 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
WO2012040137A1 (en) * 2010-09-23 2012-03-29 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CA2868240A1 (en) * 2012-05-30 2013-12-05 F. Hoffmann-La Roche Ag Triazolo compounds as pde10 inhibitors
LT2970303T (lt) * 2013-03-15 2017-07-25 Hydra Biosciences, Inc. Pakeistieji ksantinai ir jų panaudojimo metodai
EA030958B1 (ru) 2013-05-10 2018-10-31 Джилид Аполло, Ллс Ингибиторы акк и их применение
BR112015028152A2 (pt) 2013-05-10 2017-07-25 Nimbus Apollo Inc inibidores de acc e usos dos mesmos
EA201591962A1 (ru) 2013-05-10 2016-06-30 Нимбус Аполло, Инк. Ингибиторы акк и их применение
US9988399B2 (en) * 2013-05-10 2018-06-05 Gilead Apollo, Llc Bicyclic compounds as ACC inhibitors and uses thereof
CN105646492B (zh) * 2014-11-14 2019-04-09 中国医学科学院药物研究所 含五元芳杂环的取代黄嘌呤类化合物及其制备方法和用途
DE102017000359A1 (de) 2016-08-26 2018-03-01 Bihl+Wiedemann Gmbh Diagnose-Repeater für AS-Interface Netze
CN114874209B (zh) * 2017-03-07 2024-08-06 豪夫迈·罗氏有限公司 噁二唑瞬时受体电位通道抑制剂
CN112724141A (zh) * 2021-01-21 2021-04-30 南京艾美斐生物医药科技有限公司 一种gpr109a蛋白受体抑制剂及其制备和应用
MX2024009581A (es) * 2022-02-03 2024-08-13 De Shaw Res Llc Compuestos de uracilo n3-sustituidos como inhibidores de trpa1.
EP4658262A1 (en) * 2023-01-30 2025-12-10 D.E. Shaw Research, LLC Bicyclic imide compounds as trpa1 inhibitors
AR133217A1 (es) * 2023-07-10 2025-09-10 De Shaw Res Llc Inhibidores de trpa1 bicíclicos y monocíclicos

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2797220A (en) 1954-12-02 1957-06-25 Univ Michigan Substituted paraxanthines
GB8906792D0 (en) 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
IL100088A (en) 1990-11-21 1995-07-31 Smithkline Beecham Corp FNT inhibitor preparations containing histogenic transducts converted at positions 1, 3, and 8
AU3725893A (en) 1992-02-21 1993-09-13 Smithkline Beecham Corporation TNF inhibitors
CA2112239C (en) 1992-03-04 2000-05-09 James A. Bianco Enantiomeric hydroxylated xanthine compounds
US5473070A (en) 1992-11-16 1995-12-05 Cell Therapeutics, Inc. Substituted long chain alcohol xanthine compounds
US6469017B1 (en) 1998-01-16 2002-10-22 Cell Therapeutics, Inc. Method of inhibiting interleukin-12 signaling
US6693105B1 (en) 1992-11-16 2004-02-17 Cell Therapeutics, Inc. Hydroxyl-containing compounds
US5804584A (en) 1992-11-16 1998-09-08 Cell Therapeutics, Inc. Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms
IL109161A0 (en) 1993-03-31 1994-06-24 Cell Therapeutics Inc Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same
US5670506A (en) 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines
WO1994024133A1 (en) 1993-04-09 1994-10-27 Cell Therapeutics, Inc. Ring-substituted cell signaling inhibitors
WO1995020589A1 (en) 1994-01-28 1995-08-03 Cell Therapeutics, Inc. Cell signaling inhibitors
US6780865B1 (en) 1994-02-18 2004-08-24 Cell Therapeutics, Inc. Compounds having selective hydrolytic potentials
US6103730A (en) 1994-03-24 2000-08-15 Cell Therapeutics, Inc. Amine substituted compounds
EP0746557A4 (en) 1994-02-18 1997-05-02 Cell Therapeutics Inc INTRACELLULAR SIGNALING MEDIATORS
US6878715B1 (en) * 1994-02-18 2005-04-12 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
US5807861A (en) 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
US6323201B1 (en) * 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
AR015966A1 (es) 1997-10-17 2001-05-30 Smithkline Beecham Corp Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
JP2002541258A (ja) 1999-04-09 2002-12-03 セル セラピューティクス インコーポレーテッド インターリューキン−１２シグナルを阻害するための治療用化合物及びその使用方法
US20030207901A1 (en) 1999-07-27 2003-11-06 Cell Therapeutics, Inc. Hydroxyl-containing compounds
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
US6586429B2 (en) * 2000-11-29 2003-07-01 Cell Therapeutics, Inc. Tricyclic fused xanthine compounds and their uses
SK286975B6 (sk) 2001-02-24 2009-08-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xantínové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
WO2002084298A2 (en) 2001-04-11 2002-10-24 Glaxo Group Limited Medicaments which are modulators of hm74 and/or hm74a activity
DE60225556D1 (de) * 2001-07-03 2008-04-24 Novo Nordisk As Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
US7074798B2 (en) * 2002-02-25 2006-07-11 Eisai Co., Ltd Xanthine derivative and DPPIV inhibitor
US7482337B2 (en) 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
CN1227492C (zh) * 2003-03-11 2005-11-16 张跃 一种吸收式空调主体
GB0319124D0 (en) * 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
CN101103030B (zh) 2004-02-14 2010-10-13 史密丝克莱恩比彻姆公司 具有hm74a受体活性的药物
BRPI0517458A (pt) * 2004-10-22 2008-10-07 Smithkline Beecham Corp derivados da xantina com atividade para o receptor hm74a
US20090209561A1 (en) * 2004-10-22 2009-08-20 Richard Jonathan Daniel Hatley Xanthine Derivatives with HM74A Receptor Activity
WO2006045564A1 (en) 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
US20080221108A1 (en) 2005-02-14 2008-09-11 Richard Hatley Anthranilic Acid Derivatives As Hm74A Receptor Agonists
GB0516462D0 (en) * 2005-08-10 2005-09-14 Smithkline Beecham Corp Novel compounds
JP2009504592A (ja) * 2005-08-10 2009-02-05 スミスクライン・ビーチャム・コーポレイション 選択的ｈｍ７４ａアゴニストとしてのキサンチン誘導体
DE102008009758A1 (de) * 2008-02-18 2009-08-20 Beiersdorf Ag Verwendung von 3-(4-Hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)-propan-1-on zur verbesserten Hautkonturierung bzw. gegen Cellulite
AU2009324811B2 (en) 2008-12-08 2013-01-24 Glaxosmithkline Llc Novel compounds

Also Published As

Publication number Publication date
CR9749A (es) 2008-05-22
CY1111757T1 (el) 2015-10-07
JP2009504591A (ja) 2009-02-05
EP2272848B1 (en) 2012-12-26
HRP20100725T1 (hr) 2011-01-31
US8143264B2 (en) 2012-03-27
KR20080038396A (ko) 2008-05-06
EA014556B1 (ru) 2010-12-30
MX2008001929A (es) 2008-03-24
MX2008001931A (es) 2008-03-24
AU2006278215A1 (en) 2007-02-15
MA29692B1 (fr) 2008-08-01
HK1116779A1 (en) 2009-01-02
EP2272848A1 (en) 2011-01-12
US20100179128A1 (en) 2010-07-15
BRPI0614270A2 (pt) 2011-03-22
EP1912991B1 (en) 2010-11-10
EA200800564A1 (ru) 2008-08-29
PE20070405A1 (es) 2007-05-06
AU2006278216A1 (en) 2007-02-15
NO20081211L (no) 2008-05-08
US20100168122A1 (en) 2010-07-01
PT1912991E (pt) 2011-01-17
ES2401128T3 (es) 2013-04-17
EP1912992A1 (en) 2008-04-23
CR9748A (es) 2008-05-05
KR20080034993A (ko) 2008-04-22
IL189081A0 (en) 2008-08-07
ATE487719T1 (de) 2010-11-15
US20110257205A1 (en) 2011-10-20
WO2007017262A1 (en) 2007-02-15
MY142067A (en) 2010-08-30
PL1912991T3 (pl) 2011-04-29
IL189083A0 (en) 2008-08-07
AR055369A1 (es) 2007-08-22
DK1912991T3 (da) 2011-02-21
CA2618963A1 (en) 2007-02-15
JP5112316B2 (ja) 2013-01-09
SI1912991T1 (sl) 2011-03-31
EA200800555A1 (ru) 2008-08-29
WO2007017261A1 (en) 2007-02-15
DE602006018151D1 (de) 2010-12-23
JP2009504592A (ja) 2009-02-05
BRPI0615145A2 (pt) 2009-11-03
CA2626723A1 (en) 2007-02-15
TW200800217A (en) 2008-01-01
NZ565494A (en) 2011-06-30
EP1912991A1 (en) 2008-04-23
MA29693B1 (fr) 2008-08-01

Similar Documents

Publication Publication Date Title
NO20081212L (no) Xantinderivater som selektive HM74A agonister
NO20072548L (no) Xantinderivater med HM74A reseptoraktivitet
NO20070487L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
NO20090266L (no) Piperazinylderivater anvendelige i behandlingen av GPR38 receptormedierte sykdommer
NO20082124L (no) Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
NO20071246L (no) Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer.
NO20071776L (no) Kinoksaliner som B RAF inhibitorer.
NO20085176L (no) Fenyl substituerte heteroaryl-derivater og andvendelse som anti-tumor agenter
NO20064584L (no) Tetrahydropyridoindolderivater
NO20073719L (no) Kjemiske forbindelser
NO20072784L (no) Pyridenkarboksamidderivater for anvendelse som anticancer midler
NO20082709L (no) Kjemiske forbindelser
TW200606162A (en) Pyrazolopyridine derivatives
WO2007011833A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
TN2009000128A1 (en) Dihydropyridine derivatives useful as protein kinase inhibitors
NO20064151L (no) Nye forbindelser
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
WO2009062576A3 (en) Benzimidazoledihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same
NO20061952L (no) Pyrimidin-2-aminderivater og deres anvendelse som A2B-adenosinreseptorantagonister
WO2006085113A3 (en) 2-substituted 5-membered heteroaryl carboxylates as hm74a receptor agonists
WO2006096444A3 (en) Chemical compounds
MA32224B1 (fr) Derives de (pyrazolyl-carbonyl) imidazolidinone pour le traitement de maladies retrovirales
NO20090067L (no) Farmasoytiske kombinasjoner for behandling av respiratoriske sykdommer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application